Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr451.20 DKK
Change Today -1.90 / -0.42%
Volume 627.0K
COLOB On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Mexico
Frankfurt
As of 11:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

coloplast-b (COLOB) Snapshot

Open
kr454.60
Previous Close
kr453.10
Day High
kr456.50
Day Low
kr443.30
52 Week High
04/15/15 - kr581.00
52 Week Low
06/16/15 - kr413.10
Market Cap
99.3B
Average Volume 10 Days
503.5K
EPS TTM
kr14.97
Shares Outstanding
202.0M
EX-Date
05/7/15
P/E TM
30.1x
Dividend
kr12.00
Dividend Yield
2.66%
Current Stock Chart for COLOPLAST-B (COLOB)

Related News

No related news articles were found.

coloplast-b (COLOB) Related Businessweek News

No Related Businessweek News Found

coloplast-b (COLOB) Details

Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company offers ostomy care products for intestinal dysfunction resulting from disease, accident, and congenital disorder. Its ostomy care products include colostomy, ileostomy, and urostomy bags under the SenSura brand; and SenSura Mio, a colostomy product with elastic adhesive that fits individual body shapes, as well as ostomy accessories under the Brava brand. The company also provides urology care products for people suffering from diseases and symptoms of the urinary system, such as urinary incontinence, kidney stones, enlarged prostate, impotence, and pelvic floor prolapse, as well as the male reproductive system. Its disposable surgical devices include prostate catheters and stents used for urological and gynaecological applications before, during, and after surgery under the Porgès brand; vaginal slings to restore continence; synthetic mesh products to treat weak pelvic floor; and penile implants for men. In addition, the company provides continence care products comprising SpeediCath catheters that offer catherisation for both genders; and Peristeen, an anal irrigation system for controlled emptying of the bowels. Further, it offers wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products consisting of disinfectant liquids or creams used to protect and treat the skin and to clean wounds. Additionally, Coloplast A/S offers Interdry AG, a textile placed in a skin fold to absorb moisture for the treatment and prevention of skin fold problems, such as fungal infections, damaged skin, or odour nuisance. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies. Coloplast A/S was founded in 1954 and is headquartered in Humlebaek, Denmark.

10,000 Employees
Last Reported Date: 08/11/15
Founded in 1954

coloplast-b (COLOB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr8.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr1.0M
Executive Vice President of Global Operations
Total Annual Compensation: kr1.3M
Executive Vice President of Chronic Care
Total Annual Compensation: kr1.6M
Compensation as of Fiscal Year 2014.

coloplast-b (COLOB) Key Developments

Coloplast A/S Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Coloplast A/S announced unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported revenue of DKK 3,540 million compared to DKK 3,134 million a year ago. Operating profit was DKK 1,073 million compared to DKK 1,050 million a year ago. Profit before tax was DKK 933 million compared to DKK 1,057 million a year ago. Net profit for the period was DKK 709 million compared to DKK 788 million a year ago. Diluted EPS was DKK 3.22 compared to DKK 3.69 a year ago. EBITDA was DKK 1,197 million compared to DKK 1,156 million a year ago. Cash flows from operating activities were DKK 1,095 million compared to DKK 991 million a year ago. Investments in property, plant and equipment, gross was DKK 111 million compared to DKK 137 million a year ago. Free cash flow was DKK 985 million or DKK 4.7 per share compared to DKK 1,080 million or DKK 5.1 per share a year ago. Return on equity was 47% compared to 52% a year ago. Net asset value per share was DKK 26 compared to DKK 25 a year ago. Operating cash flow amounted to almost DKK 2 billion and was slightly lower than the same period last year. For the nine months, the company reported revenue of DKK 10,288 million compared to DKK 9,214 million a year ago. Operating profit was DKK 3,286 million compared to DKK 2,047 million a year ago. Profit before tax was DKK 3,053 million compared to DKK 2,079 million a year ago. Net profit for the period was DKK 2,321 million compared to DKK 1,549 million a year ago. Diluted EPS was DKK 10.88 compared to DKK 7.23 year ago. Cash flows from operating activities were DKK 1,958 million compared to DKK 1,988 million a year ago. Investments in property, plant and equipment under construction were DKK 404 million compared to DKK 293 million a year ago. EBITDA was DKK 3,649 million compared to DKK 2,362 million a year ago. Investments in property, plant and equipment, gross was DKK 426 million compared to DKK 347 million a year ago. Free cash flow was DKK 1,950 million or DKK 9.2 per share compared to DKK 1,611 million or DKK 7.6 per share a year ago. EBIT before special items increased by 8% to DKK 3,286 million. Return on equity was 51% compared to 34% a year ago. The company continues to expect organic revenue growth of about 7% and of about 12% in DKK. The company continues to expect the EBIT margin to be about 32%, both at constant exchange rates and in DKK. Capital expenditure is still expected to be around DKK 650 million and is driven especially by investments in more capacity and for new products, like SenSura Mio, Biatain Silicone and Compact Eve. The effective tax rate is still expected to be about 24%.

Coloplast A/S, Q3 2015 Earnings Call, Aug 11, 2015

Coloplast A/S, Q3 2015 Earnings Call, Aug 11, 2015

Coloplast A/S Provides Earnings Guidance for the Full Year of 2015

Coloplast A/S provided earnings guidance for the full year of 2015. The company's revenue expectations for the full-year are revised from an organic revenue growth of 8-9% to an organic revenue growth of around 7%. The expected EBIT margin for 2014/15 is lowered from around 34% at constant exchange rates and in DKK to around 32%, both at constant exchange rates and in DKK. The EBIT margin is lowered partly due to expected lower sales. Guidance for capital expenditure remains unchanged at around DKK 650 million, and the effective tax rate is still expected to be about 24%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COLOB:DC kr451.20 DKK -1.90

COLOB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $197.47 USD +0.98
Smith & Nephew PLC 1,163 GBp +29.00
Teleflex Inc $132.49 USD -0.61
William Demant Holding A/S kr539.00 DKK -5.00
View Industry Companies
 

Industry Analysis

COLOB

Industry Average

Valuation COLOB Industry Range
Price/Earnings 30.5x
Price/Sales 7.1x
Price/Book 16.5x
Price/Cash Flow 28.9x
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLOPLAST-B, please visit www.coloplast.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.